Clinical effects on disease severity and quality of life of myasthenia gravis patients based on telemedical treatment with point-of-care diagnostics in the integrated myasthenia center (iMZ) - a pilot study

Clinical effects on disease severity and quality of life of myasthenia gravis patients based on telemedical treatment with point-of-care diagnostics in the integrated myasthenia center (iMZ) - a pilot study - MyaLink

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00029907

Enrollment

Registered

2022-08-19

Start date

2023-04-25

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G70.0

Interventions

Group 1: Use of wearables / MyaLink app (intervention group) Group 2: without using the wearables / MyaLink app (control group)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Participants must suffer from myasthenia gravis (ICD-10: G70.0), the diagnosis must have existed for at least 6 months Participants must be treated in the iMZ of the Charité Berlin Participants must communicate in German without an interpreter Age of majority, minimum age 18 years

Exclusion criteria

Exclusion criteria: Organic brain diseases (ICD-10: F0x) Intellectual disability (ICD-10: F7x) Physical illnesses with limitations that make regular participation and data entry via a smartphone impossible Inability to conduct the study and understand the risks involved Patients with a somatic, psychiatric or neurological disease or treatment that can impair cognitive functions or are not stable under drug treatment and could have an impact on the parameters to be examined. Patients who do not have a smartphone or tablet (operating system requirement at least iOS 14 or Android 9).

Design outcomes

Primary

Measure	Time frame
Measurement of adherence to the entry of ePROMs (electronic Patient Reported Outcome Measures) and collection of vital parameters by the participants by measuring the proportion of actual entries compared to the planned queries over a period of three months.	—

Secondary

Measure	Time frame
Assessment of usability (System Usability Scale), drop out rate, Myasthenia gravis Activities of Daily Living, Myasthenia gravis quality of daily living, Quantitative myasthenia gravis score, Patient Health Questionnaire, Chalder Fatigue Scale, Hospital anxiety and depression scale, Absolute number of hospital stays (normal ward, intensive care ward) during the intervention period, Absolute number of rescue center contacts	—

Measure

Time frame

Assessment of usability (System Usability Scale), drop out rate, Myasthenia gravis Activities of Daily Living, Myasthenia gravis quality of daily living, Quantitative myasthenia gravis score, Patient Health Questionnaire, Chalder Fatigue Scale, Hospital anxiety and depression scale, Absolute number of hospital stays (normal ward, intensive care ward) during the intervention period, Absolute number of rescue center contacts

—

Countries

Germany

Contacts

Public ContactMaike Stein

Klinik für Neurologie

maike.stein@charite.de030450539734

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 5, 2026